Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Up 1.1 %

Supernus Pharmaceuticals stock opened at $33.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a fifty day simple moving average of $35.49 and a two-hundred day simple moving average of $35.05. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 30.89 and a beta of 0.83.

Insiders Place Their Bets

In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,104 shares of company stock worth $440,263. Corporate insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. Barclays PLC increased its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after buying an additional 51,005 shares during the period. Segall Bryant & Hamill LLC bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth about $791,000. Geode Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the period. Franklin Resources Inc. raised its stake in shares of Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $1,498,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.